114 related articles for article (PubMed ID: 35219004)
1. The prognostic significance of serum interferon-gamma (IFN-γ) in hormonally dependent breast cancer.
Todorović-Raković N; Milovanović J; Greenman J; Radulovic M
Cytokine; 2022 Apr; 152():155836. PubMed ID: 35219004
[TBL] [Abstract][Full Text] [Related]
2. Can granulysin provide prognostic value in primary breast cancer?
Milovanović J; Todorović-Raković N; Vujasinović T; Greenman J; Mandušić V; Radulovic M
Pathol Res Pract; 2022 Sep; 237():154039. PubMed ID: 35905663
[TBL] [Abstract][Full Text] [Related]
3. The significance of HOXB7 and IL17RB serum levels in prognosis of hormonally dependent breast cancer: A pilot study.
Todorović-Raković N; Milovanović J; Greenman J; Radulovic M
Adv Med Sci; 2021 Sep; 66(2):359-365. PubMed ID: 34304115
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients.
Milovanović J; Vujasinović T; Todorović-Raković N; Greenman J; Hranisavljević J; Radulovic M
Pathol Res Pract; 2023 Dec; 252():154923. PubMed ID: 37948997
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.
Heimes AS; Härtner F; Almstedt K; Krajnak S; Lebrecht A; Battista MJ; Edlund K; Brenner W; Hasenburg A; Sahin U; Gehrmann M; Hengstler JG; Schmidt M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003293
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer.
Milovanović J; Todorović-Raković N; Radulovic M
Cytokine; 2019 Jun; 118():93-98. PubMed ID: 29482885
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study.
Todorović-Raković N; Milovanović J; Durosaro SO; Radulovic M
Pathol Res Pract; 2021 Jun; 222():153430. PubMed ID: 33839437
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
11. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
Berger K; Rhost S; Rafnsdóttir S; Hughes É; Magnusson Y; Ekholm M; Stål O; Rydén L; Landberg G
BMC Cancer; 2021 Feb; 21(1):185. PubMed ID: 33618683
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).
Kim JW; Lee S; Kim HS; Choi YJ; Yoo J; Park KU; Kang SY; Park YH; Jung KH; Ahn JH; Oh HS; Choi IS; Kim HJ; Lee KH; Lee S; Seo JH; Park IH; Lee KE; Kim HY; Park KH
Cytokine; 2021 Jun; 142():155487. PubMed ID: 33770643
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
14. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
15. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M
Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
